

Atopic Dermatitis Enrollment Form



Fax Referral To: 1-877-232-5455
Address: 500 Ala Moana Blvd., Bldg 1 Honolulu, HI 96813

Phone: 1-808-254-2727
NCPDP: 1203417

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: _____ DOB: _____ Gender: Male Female

Address: _____ City, State, ZIP Code: _____

Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)

Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone: _____ Alternate Phone: _____

Email: _____ Last Four of SSN: _____ Primary Language: _____

Parent/Caregiver/Legal Guardian Name (Last, First): _____ Relationship to patient: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____

NPI #: _____ DEA #: _____ Group or Hospital: _____

Address: _____ City, State, ZIP Code: _____

Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION *Please fax copy of prescription and insurance cards with this form, if available (front and back)*

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Ship to: Patient Office Other: _____

Diagnosis (ICD-10):

L20.9 Atopic Dermatitis, Unspecified Other Code: _____ Description: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ in/cm TB Test Result: _____ Date: _____

Atopic Dermatitis Enrollment Form

Please Complete Patient, Prescriber and Patient Clinical Information

Patient Name: _____ Patient DOB: _____ Patient Phone: _____

Prescriber Name: _____ Prescriber Phone: _____

Patient Clinical Information:

Allergies: _____

Weight: _____ lb/kg Height: _____ In/cm TB Test Result: _____ Date: _____

5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Adbry	<input type="checkbox"/> 2x150 mg/mL PFS <input type="checkbox"/> 4x150 mg/mL PFS	Loading Dose: <input type="checkbox"/> Inject 600 mg (4x150 mg/mL) SC on Day 1 <input type="checkbox"/> Inject 300 mg (2x150 mg/mL) SC on Day 1	Quantity: <input type="checkbox"/> 2x150 mg/mL PFS <input type="checkbox"/> 4x150 mg/mL PFS Refill: 0
	<input type="checkbox"/> 2x150 mg/mL PFS <input type="checkbox"/> 4x150 mg/mL PFS	Maintenance Dose: <input type="checkbox"/> Inject 300 mg (2X150 mg/mL) SC every other week starting on Day 15 <input type="checkbox"/> Inject 300 mg (2X150 mg/mL) SC every 4 weeks <input type="checkbox"/> Inject 150 mg (1X150 mg/mL) SC every other week starting on Day 15	Quantity: <input type="checkbox"/> 28 days <input type="checkbox"/> 84 days Refill: _____
<input type="checkbox"/> Cibinqo	<input type="checkbox"/> 50 mg <input type="checkbox"/> 100 mg <input type="checkbox"/> 200 mg	<input type="checkbox"/> Take 1 tablet by mouth once daily <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Dupixent	For use in patients ≥ 6 months and older: <input type="checkbox"/> 200 mg/1.14 mL (Carton of two pre-filled syringes with needle shield) <input type="checkbox"/> 300 mg/2 mL (Carton of two pre-filled syringes with needle shield)	Adult Patients: <input type="checkbox"/> 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every other week thereafter Pediatric Patients (6 months to 5 years of age): 5 to less than 15 kg: <input type="checkbox"/> 200 mg (one pre-filled syringe) every 4 weeks 15 to less than 30 kg: <input type="checkbox"/> 300 mg (one pre-filled syringe) every 4 weeks Pediatric Patients (6 years to 17 years of age) 15 to less than 30 kg: <input type="checkbox"/> 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every 4 weeks thereafter 30 to less than 60 kg: <input type="checkbox"/> 400 mg (two 200 mg injections) subcutaneously on Day 1, then 200 mg subcutaneously every 2 weeks thereafter 60 kg or more: <input type="checkbox"/> 600 mg (two 300 mg injections) subcutaneously on Day 1, then 300 mg subcutaneously every 2 weeks thereafter	Quantity: _____ (# of injections) Refills: _____
	For use in patients ≥ 2 years of age and older: <input type="checkbox"/> 200 mg/1.14 mL (Carton of two single dose pre-filled pens) <input type="checkbox"/> 300 mg/2 mL (Carton of two single dose pre-filled pens)		
<input type="checkbox"/> Rinvoq	<input type="checkbox"/> 15 mg <input type="checkbox"/> 30 mg	<input type="checkbox"/> Take 1 tablet by mouth once daily <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Other:	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.